Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 7

1.

A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.

Archibald M, Pritchard T, Nehoff H, Rosengren RJ, Greish K, Taurin S.

Int J Nanomedicine. 2016 Jan 8;11:179-200. doi: 10.2147/IJN.S97286. eCollection 2016.

2.

Role of solute carriers in response to anticancer drugs.

Li Q, Shu Y.

Mol Cell Ther. 2014 May 27;2:15. doi: 10.1186/2052-8426-2-15. eCollection 2014. Review.

3.

OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies.

Roth M, Obaidat A, Hagenbuch B.

Br J Pharmacol. 2012 Mar;165(5):1260-87. doi: 10.1111/j.1476-5381.2011.01724.x. Review.

4.

Expression and analysis of two novel rat organic cation transporter homologs, SLC22A17 and SLC22A23.

Bennett KM, Liu J, Hoelting C, Stoll J.

Mol Cell Biochem. 2011 Jun;352(1-2):143-54. doi: 10.1007/s11010-011-0748-y. Epub 2011 Feb 27.

5.

Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.

Morrow CJ, Ghattas M, Smith C, Bönisch H, Bryce RA, Hickinson DM, Green TP, Dive C.

Cancer Res. 2010 Jul 15;70(14):5931-41. doi: 10.1158/0008-5472.CAN-10-0694. Epub 2010 Jun 15.

6.

The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5.

Aouida M, Poulin R, Ramotar D.

J Biol Chem. 2010 Feb 26;285(9):6275-84. doi: 10.1074/jbc.M109.046151. Epub 2009 Dec 25.

7.

Muscarinic receptors and ligands in cancer.

Shah N, Khurana S, Cheng K, Raufman JP.

Am J Physiol Cell Physiol. 2009 Feb;296(2):C221-32. doi: 10.1152/ajpcell.00514.2008. Epub 2008 Nov 26. Review.

Items per page

Supplemental Content

Write to the Help Desk